GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach GSK as a Graham-style bargain hunter. It is a large vaccines and medicines business, with 66,841 employees and a portfolio spanning vaccines, specialty medicines, and general medicines. That scale can create a moat, but the numbers show mixed quality. In the latest quarter shown, 2026-Q2, GSK earned $435.0 million on $8.4 billion of revenue—a 5.17% net margin. The supplied data show revenue growth of 5.30% but profit growth of -69.85%, so earnings quality is under pressure. Return on equity is high at 33.38% (FairStock calculation), but return on capital employed is only 10.01%, suggesting the equity return may be flattered by leverage or other factors. Debt-to-equity is 1.06, and the Altman Z-Score is 1.86, both cautionary. Cash generation is a positive: trailing free cash flow is $5.3 billion, a 4.7% FCF yield, supporting a 3.62% dividend. At the 2026-10-13 close of $46.27, the P/E is 14.69, P/B is 3.93, and EV/EBITDA is 12.68 (FairStock calculations). A Graham Number of $17.66 implies a -162% margin of safety, so this is not a classic Graham bargain. The Piotroski F-Score is 7/9, and the FairStock score is 67/100. The Lynch category is none because only 0 years of filed results are available, needing 3. GSK looks like a fairly priced defensive healthcare company with a modest yield, but the falling profits, thin margin, and leverage mean I would want evidence of durable profit recovery before calling it cheap.

In plain English: GSK is a large healthcare company that researches and makes vaccines and medicines. In the latest quarter shown, second quarter of 2026, it earned $435 million on $8.4 billion of revenue, a thin 5.17% margin, and the supplied figures show profit falling sharply. At $46.27, the shares look full relative to the company’s asset value, though cash flow and a 3.62% dividend give some support.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer